Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus Directory of Open Access Journals kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

Mechanisms by Which Liposomes Improve Inhaled Drug Delivery for Alveolar Diseases

Title: Mechanisms by Which Liposomes Improve Inhaled Drug Delivery for Alveolar Diseases
Authors: Laura T. Ferguson; Xiaonan Ma; Jacob W. Myerson; Jichuan Wu; Patrick M. Glassman; Marco E. Zamora; Elizabeth D. Hood; Michael Zaleski; Mengwen Shen; Eno-Obong Essien; Vladimir V. Shuvaev; Jacob S. Brenner
Source: Advanced NanoBiomed Research, Vol 3, Iss 3, Pp n/a-n/a (2023)
Publisher Information: Wiley-VCH, 2023.
Publication Year: 2023
Collection: LCC:Biotechnology; LCC:Medical technology
Subject Terms: inhaled; nanomedicine; nintedanib; pulmonary fibrosis; surfactant; Biotechnology; TP248.13-248.65; Medical technology; R855-855.5
Description: Diseases of the pulmonary alveolus, such as pulmonary fibrosis, are leading causes of morbidity and mortality, but exceedingly few drugs are developed for them. A major reason for this gap is that after inhalation, drugs are quickly whisked away from alveoli due to their high perfusion. To solve this problem, the mechanisms by which nano‐scale drug carriers dramatically improve lung pharmacokinetics using an inhalable liposome formulation containing nintedanib, an antifibrotic for pulmonary fibrosis, are studied. Direct instillation of liposomes in murine lung increases nintedanib's total lung delivery over time by 8000‐fold and lung half life by tenfold, compared to oral nintedanib. Counterintuitively, it is shown that pulmonary surfactant neither lyses nor aggregates the liposomes. Instead, each lung compartment (alveolar fluid, alveolar leukocytes, and parenchyma) elutes liposomes over 24 h, likely serving as “drug depots.” After deposition in the surfactant layer, liposomes are transferred over 3–6 h to alveolar leukocytes (which take up a surprisingly minor 1–5% of total lung dose instilled) in a nonsaturable fashion. Further, all cell layers of the lung parenchyma take up liposomes. These and other mechanisms elucidated here should guide engineering of future inhaled nanomedicine for alveolar diseases.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 2699-9307
Relation: https://doaj.org/toc/2699-9307
DOI: 10.1002/anbr.202200106
Access URL: https://doaj.org/article/eb489d494be74c0a89082fbe3a8a2bcc
Accession Number: edsdoj.b489d494be74c0a89082fbe3a8a2bcc
Database: Directory of Open Access Journals